Replimune Group (REPL) News Today $13.98 -0.33 (-2.31%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$13.48 -0.50 (-3.57%) As of 02/21/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Replimune Group, Inc. (NASDAQ:REPL) Receives $19.29 Average Price Target from BrokeragesFebruary 23 at 1:15 AM | americanbankingnews.comReplimune Group (NASDAQ:REPL) Shares Up 6.1% - Still a Buy?Replimune Group (NASDAQ:REPL) Shares Up 6.1% - Here's What HappenedFebruary 21 at 2:35 PM | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Receives Average Recommendation of "Buy" from BrokeragesShares of Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) have been given a consensus recommendation of "Buy" by the eight brokerages that are covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recFebruary 20 at 4:11 AM | marketbeat.comAnalysts Issue Forecasts for Replimune Group FY2025 EarningsFebruary 18, 2025 | americanbankingnews.comReplimune Group FY2025 EPS Forecast Cut by Leerink PartnrsFebruary 18, 2025 | americanbankingnews.comLeerink Partnrs Predicts Weaker Earnings for Replimune GroupReplimune Group, Inc. (NASDAQ:REPL - Free Report) - Analysts at Leerink Partnrs decreased their FY2025 earnings estimates for shares of Replimune Group in a research note issued on Wednesday, February 12th. Leerink Partnrs analyst J. Chang now forecasts that the company will post earnings of ($2.February 17, 2025 | marketbeat.comFY2025 EPS Estimates for Replimune Group Lowered by WedbushReplimune Group, Inc. (NASDAQ:REPL - Free Report) - Analysts at Wedbush cut their FY2025 earnings per share estimates for Replimune Group in a note issued to investors on Wednesday, February 12th. Wedbush analyst R. Driscoll now anticipates that the company will post earnings of ($3.07) per shareFebruary 17, 2025 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Short Interest Up 16.7% in JanuaryReplimune Group, Inc. (NASDAQ:REPL - Get Free Report) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 8,470,000 shares, a growth of 16.7% from the January 15th total of 7,260,000 shares. Based on an average daily trading volume, of 885,200 shares, the short-interest ratio is presently 9.6 days.February 16, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Stock Price Expected to Rise, HC Wainwright Analyst SaysFebruary 15, 2025 | americanbankingnews.comReplimune price target raised to $22 from $21 at H.C. WainwrightFebruary 13, 2025 | markets.businessinsider.comNavigating Uncertainty: Replimune Group’s Strategic Challenges Amid Clinical Trials and Global RisksFebruary 13, 2025 | msn.comReplimune stock target raised to $22 at H.C. WainwrightFebruary 13, 2025 | msn.comBarclays Keeps Their Buy Rating on Replimune Group (REPL)February 13, 2025 | markets.businessinsider.comReplimune Group (NASDAQ:REPL) Price Target Raised to $22.00HC Wainwright boosted their target price on shares of Replimune Group from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Thursday.February 13, 2025 | marketbeat.comReplimune price target raised to $19 from $16 at WedbushFebruary 12, 2025 | markets.businessinsider.comReplimune price target raised to $21 from $18 at LeerinkFebruary 12, 2025 | markets.businessinsider.comReplimune: A Misunderstood Contender In OncolyticsFebruary 12, 2025 | seekingalpha.comReplimune reports Q3 EPS (79c) vs (77c) last yearFebruary 12, 2025 | markets.businessinsider.comReplimune Group (NASDAQ:REPL) Announces Earnings ResultsReplimune Group (NASDAQ:REPL - Get Free Report) announced its earnings results on Wednesday. The company reported ($0.79) EPS for the quarter, missing analysts' consensus estimates of ($0.70) by ($0.09).February 12, 2025 | marketbeat.comReplimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate UpdateFebruary 12, 2025 | globenewswire.comReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 7, 2025 | globenewswire.comReplimune Group (REPL) Expected to Announce Earnings on ThursdayReplimune Group (NASDAQ:REPL) will be releasing earnings before the market opens on Thursday, February 13.February 7, 2025 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Receives Average Rating of "Buy" from BrokeragesShares of Replimune Group, Inc. (NASDAQ:REPL - Get Free Report) have earned a consensus rating of "Buy" from the eight ratings firms that are covering the firm, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation and one has given a strong buy recommeJanuary 26, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Stock Price Down 3.5% - Here's What HappenedReplimune Group (NASDAQ:REPL) Stock Price Down 3.5% - What's Next?January 24, 2025 | marketbeat.comWedbush Brokers Raise Earnings Estimates for Replimune GroupReplimune Group, Inc. (NASDAQ:REPL - Free Report) - Research analysts at Wedbush increased their Q3 2025 earnings estimates for shares of Replimune Group in a note issued to investors on Tuesday, January 21st. Wedbush analyst R. Driscoll now expects that the company will earn ($0.63) per share foJanuary 23, 2025 | marketbeat.comReplimune price target raised to $21 from $17 at H.C. WainwrightJanuary 22, 2025 | markets.businessinsider.comStrong Buy Rating for Replimune Group Due to Promising RP1 + Opdivo Results and Favorable FDA ReviewJanuary 22, 2025 | markets.businessinsider.comReplimune's SWOT analysis: oncolytic immunotherapy stock faces pivotal yearJanuary 22, 2025 | msn.comBMO Capital Markets Forecasts Strong Price Appreciation for Replimune Group (NASDAQ:REPL) StockBMO Capital Markets upped their target price on shares of Replimune Group from $18.00 to $27.00 and gave the company an "outperform" rating in a research report on Wednesday.January 22, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Stock Price Up 6% After Analyst UpgradeReplimune Group (NASDAQ:REPL) Trading Up 6% Following Analyst UpgradeJanuary 22, 2025 | marketbeat.comReplimune Group (NASDAQ:REPL) Given New $21.00 Price Target at HC WainwrightHC Wainwright increased their price target on Replimune Group from $17.00 to $21.00 and gave the company a "buy" rating in a research note on Wednesday.January 22, 2025 | marketbeat.comReplimune announces BLA acceptance, priority review for RP1January 21, 2025 | markets.businessinsider.comReplimune Stock Soars 16% on FDA Priority Review for Advanced Melanoma TherapyJanuary 21, 2025 | uk.finance.yahoo.comReplimune stock price target raised to $27 by BMO CapitalJanuary 21, 2025 | msn.comReplimune stock soars on FDA priority review for melanoma treatmentJanuary 21, 2025 | in.investing.comFDA accepts Replimune's advanced melanoma therapy BLAJanuary 21, 2025 | msn.comReplimune Announces Biologics License Application Acceptance and Priority Review for RP1 for the Treatment of Advanced MelanomaJanuary 21, 2025 | markets.businessinsider.comReplimune's BLA For RP1-Nivolumab Combo Gets FDA Approval For Advanced Melanoma, Stock SurgesJanuary 21, 2025 | markets.businessinsider.comReplimune Group (NASDAQ:REPL) Shares Gap Up - Time to Buy?Replimune Group (NASDAQ:REPL) Shares Gap Up - Time to Buy?January 21, 2025 | marketbeat.comReplimune Group (REPL) Receives a Buy from BarclaysJanuary 16, 2025 | markets.businessinsider.comReplimune Group’s Strategic Advances Highlight Promising Potential in Oncolytic Virus TherapyJanuary 14, 2025 | markets.businessinsider.comReplimune Group (NASDAQ:REPL) Shares Down 6.6% - What's Next?Replimune Group (NASDAQ:REPL) Shares Down 6.6% - Time to Sell?January 14, 2025 | marketbeat.comBarclays PLC Boosts Holdings in Replimune Group, Inc. (NASDAQ:REPL)Barclays PLC lifted its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 165.5% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 158,491 shares of the company's stock after acquiring an additional 98,791 shares during the quarter.January 12, 2025 | marketbeat.comReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 10, 2025 | globenewswire.comReplimune announces RP2 development program advancesJanuary 8, 2025 | markets.businessinsider.comReplimune Group (NASDAQ:REPL) Shares Up 9.5% - Should You Buy?Replimune Group (NASDAQ:REPL) Shares Up 9.5% - What's Next?January 2, 2025 | marketbeat.comGeode Capital Management LLC Increases Stake in Replimune Group, Inc. (NASDAQ:REPL)Geode Capital Management LLC grew its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 17.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,428,301 shares of the compaDecember 30, 2024 | marketbeat.comReplimune Group, Inc. (NASDAQ:REPL) Shares Purchased by Barclays PLCBarclays PLC boosted its holdings in shares of Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 165.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 158,491 shares of the company's stock after purchasing an additional 98,791 shares during the perioDecember 28, 2024 | marketbeat.comReplimune to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 23, 2024 | globenewswire.comState Street Corp Buys 1,182,181 Shares of Replimune Group, Inc. (NASDAQ:REPL)State Street Corp boosted its position in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 102.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,340,042 shares of the company's stock after purchasing an additional 1,182,181 sDecember 23, 2024 | marketbeat.com Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address REPL Media Mentions By Week REPL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. REPL News Sentiment▼0.000.61▲Average Medical News Sentiment REPL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. REPL Articles This Week▼143▲REPL Articles Average Week Get Replimune Group News Delivered to You Automatically Sign up to receive the latest news and ratings for REPL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Avidity Biosciences News ADMA Biologics News Arcellx News Akero Therapeutics News Rhythm Pharmaceuticals News Scholar Rock News Immunovant News Apellis Pharmaceuticals News Viking Therapeutics News ACADIA Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:REPL) was last updated on 2/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredNvidia > DeepSeekEveryone's getting it all wrong … Sure, DeepSeek's reveal caused AI stocks to tumble … But, in the long ...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free REPL Stock Alerts